G-TAK: A novel combinatorial therapy for acute-on-chronic liver failure

News & Events

All News
24 June 2022

Meet us at ILC2022 on 24/06/2022, 12-13h GMT!

Don`t miss the opportunity to meet the team and receive important information about the project at ILC2022 at the EASL Community Hub! Read more.
28 January 2022

A-TANGO at Falk Symposium on Alcoholic Liver Disease

From 27-28 January 2022, the Falk Foundation Symposium on the "Pathophysiology and Clinical Management of Alcoholic Liver Disease" took place in a registration-based online format. A-TANGO coordinator, Prof. Rajiv Jalan (EFCLIF, UCL, HPX), presented a talk on "Mechanisms of recovery from and strategies for survival of severe alcoholic hepatitis and ACLF" and discussed important unsolved questions regarding the recovery from cirrhosis and episodes of ACLF.

22 December 2021

Scroll through our 1st newsletter and meet our early-career scientists

The 1st A-TANGO newsletter is out - Learn about the project's progress, our early-career scientists (ECS), this year's patient event about cirrhosis and ACLF, and upcoming scientific conferences. If you haven't received our newsletter in your inbox, but would like to stay updated on a half-yearly basis via email, please subscribe here. Let us wish you all Happy Holidays & a healthy New Year!

OUR VISION

More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterized by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Read more

OBJECTIVES

  • Obtain ethical and regulatory approval of the planned clinical studies
  • Ensure safe and regulated supply of the required drugs and placebos
  • European multicenter clinical study to establish the safety, pharmacokinetics, and efficacy of our novel therapeutic strategy
  • Explore the pathophysiological mechanisms and evaluate biomarkers
  • Evaluate our results with respect to clinical outcome, treatment impact, and quality of life
  • Exploit our results by identifying economic benefits for the healthcare system, reimbursement strategies, and potential commercial interest
  • Disseminate the therapeutic potential of our novel treatment strategy to stakeholders and increase awareness of end-stage liver disease

Read more

SCIENTIFIC COORDINATOR

Prof. Dr. Rajiv Jalan (EFCLIF)
Travessera de Gràcia 11, 7th floor
08021 Barcelona
Spain

CLINICAL STUDY SUPERVISOR

Dr. med. Cornelius Engelmann (Charité)
Augustenburger Platz 1
13353 Berlin
Germany

PROJECT
MANAGEMENT

concentris research management gmbh
Ludwigstr. 4
82256 Fürstenfeldbruck
Germany

Our vision

Clinical study

Publications

Useful links

Downloads

Liver Quiz